Literature DB >> 9892155

Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.

L Brown1, B Duce, G Miric, C Sernia.   

Abstract

Fibrosis impairs cardiac function. This project has determined the expression and deposition of collagens and fibronectin and cardiac function in the deoxycorticosterone acetate (DOCA)-salt hypertensive rat after inhibition of the renin-angiotensin system. DOCA-salt hypertension was induced in 8-wk-old male Wistar rats by uninephrectomy and administration of DOCA (25 mg every fourth day, subcutaneously) and 1% NaCl in the drinking water for 4 wk. Starting 2 wk after surgery, rats were given either oral captopril (100 mg/kg), oral candesartan cilexetil (2 mg/kg), or subcutaneous spironolactone (50 mg/kg) daily for 2 wk (reversal protocol). DOCA-salt rats failed to gain weight with markedly increased water intake and decreased food intake; drug treatment did not alter these parameters. Systolic BP increased from 116+/-5 mmHg in uninephrectomized rats to 179+/-7 mmHg in DOCA-salt rats and was not decreased by treatment (captopril 172+/-1 mmHg; candesartan 187+/-2 mmHg; spironolactone 178+/-3 mmHg). Captopril, candesartan, and spironolactone reversed the increased collagen I mRNA in DOCA-salt rats; only candesartan reversed the increased collagen III mRNA. Collagen IV mRNA was unchanged in DOCA-salt rats and following treatment. Total fibronectin mRNA increased without changing the proportion of fibronectin mRNA as the fetal isoforms EIIIA and EIIIB. Captopril, candesartan, and spironolactone reversed the increased deposition of perivascular and interstitial collagen in DOCA-salt rats; the increased cardiac fibronectin deposition was reversed by candesartan and spironolactone. Captopril, candesartan, and spironolactone also attenuated or reversed the increased diastolic stiffness and the increased dP/dt but not the increased rate-pressure products in DOCA-salt rat hearts. Thus, inhibition of the renin-angiotensin system reverses cardiac fibrosis in DOCA-salt rats and returns some indices of myocardial function to normal.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892155

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  23 in total

1.  Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

Authors:  Anthony Allan; Andrew Fenning; Scott Levick; Andrew Hoey; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase.

Authors:  David Loch; Andrew Hoey; Christophe Morisseau; Bruce O Hammock; Lindsay Brown
Journal:  Cell Biochem Biophys       Date:  2007       Impact factor: 2.194

3.  Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.

Authors:  H Peng; O A Carretero; L Raij; F Yang; A Kapke; N E Rhaleb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

4.  Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice.

Authors:  Nour-Eddine Rhaleb; Saraswati Pokharel; Umesh Sharma; Oscar A Carretero
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

5.  Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.

Authors:  Vincent Chan; Andrew Hoey; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 6.  Regulation of matrix proteins and impact on vascular structure.

Authors:  J Tuñón; M Ruiz-Ortega; J Egido
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

7.  Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.

Authors:  G Miric; C Dallemagne; Z Endre; S Margolin; S M Taylor; L Brown
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

8.  Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.

Authors:  Stevo Mirkovic; Anne-Marie L Seymour; Andrew Fenning; Anna Strachan; Solomon B Margolin; Stephen M Taylor; Lindsay Brown
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

9.  Cardiac adaptation to endurance exercise in rats.

Authors:  Andrew Fenning; Glenn Harrison; Dan Dwyer; Roselyn Rose'Meyer; Lindsay Brown
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

10.  Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.

Authors:  Natalia Tsybouleva; Lianfeng Zhang; Suetnee Chen; Rajnikant Patel; Silvia Lutucuta; Shintaro Nemoto; Gilberto DeFreitas; Mark Entman; Blase A Carabello; Robert Roberts; A J Marian
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.